HeartFlow Stock: Using AI to Combat Heart Disease
The older you get, the more you start to understand why old people spend so much time talking about their health problems. It usually starts in your mid-40s when you realize you’re at the age where you should get regular health screens. You go in for bloodwork, and the doctor says you have high cholesterol. So, you start on “the Mediterranean diet,” buy a new jogging watch, and even briefly consider kicking your methamphetamine habit getting off your ADHD medication. After a few weeks, you’re right back into your old habits, and eventually, just adopt the American solution to healthcare problems – another pill.
Cardiovascular disease is no joke. It’s the number one cause of death accounting for one out of three deaths, more than twice as many deaths as the second most common cause (cancer). About one in every six healthcare dollars is spent on heart disease, and it’s almost certain that you or someone you know will be affected by it. Given the scope of the problem, there’s likely to be lots of delicious big data lying around that we can feed to some hungry artificial intelligence (AI) algorithms which can help us save lives and make loads of money.
About HeartFlow Stock
Founded in 2007, Silicon Valley’s own HeartFlow has raised just over $577 million in disclosed funding with a current valuation of $1.3 billion, at least according to
